Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus

Condition:   Autoimmune Diseases Interventions:   Drug: Standard dose of rituximab;   Drug: Individualized dose of rituximab Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hospitals | Lupus | Research | Rituxan